Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
People's Hospital of Ningxiang City, Ningxiang, China.
Front Immunol. 2022 Sep 23;13:961325. doi: 10.3389/fimmu.2022.961325. eCollection 2022.
To evaluate Safety and efficacy of probiotic supplementation in inflammatory arthritis.
The literature on the treatment of inflammatory arthritis with probiotics has been collected in databases such as CNKI, Pubmed, Cochrane library, Embase, etc. The search time is for them to build the database until May 2022. The included literatures are randomized controlled trials (RCTs) of probiotics in the treatment of hyperuricemia and gout. The Cochrane risk assessment tool was used for quality evaluation, and the Rev Man5.3 software was used for meta-analysis.
A total of 37 records were finally included, involving 34 RCTs and 8 types of autoimmune disease (Hyperuricemia and gout, Inflammatory bowel disease arthritis, juvenile idiopathic arthritis [JIA], Osteoarthritis [OA], Osteoporosis and Osteopenia, Psoriasis, rheumatoid arthritis (RA), Spondyloarthritis). RA involved 10 RCTs (632 participants) whose results showed that probiotic intervention reduced CRP. Psoriasis involved 4 RCTs (214 participants) whose results showed that probiotic intervention could reduce PASI scores. Spondyloarthritis involved 2 RCTs (197 participants) whose results showed that probiotic intervention improved symptoms in patients. Osteoporosis and Ostepenia involving 10 RCTs (1156 participants) showed that probiotic intervention improved bone mineral density in patients. Hyperuricemia and gout involving 4 RCTs (294 participants) showed that probiotic intervention improved serum uric acid in patients. OA involving 1 RCTs (433 participants) showed that probiotic intervention improved symptoms in patients. JIA involving 2 RCTs (72 participants) showed that probiotic intervention improved symptoms in patients. Inflammatory bowel disease arthritis involving 1 RCTs (120 participants) showed that probiotic intervention improved symptoms in patients. All of the above RCTs showed that probiotics did not increase the incidence of adverse events.
Probiotic supplements may improve Hyperuricemia and gout, Inflammatory bowel disease arthritis, JIA, OA, Osteoporosis and Osteopenia, Psoriasis, RA, Spondyloarthritis. However, more randomized controlled trials are needed in the future to determine the efficacy and optimal dosing design of probiotics.
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021286425, identifier CRD42021286425.
评估益生菌补充剂在炎症性关节炎中的安全性和疗效。
在 CNKI、Pubmed、Cochrane 图书馆、Embase 等数据库中收集了益生菌治疗炎症性关节炎的文献。检索时间为自建库至 2022 年 5 月。纳入的文献为益生菌治疗高尿酸血症和痛风的随机对照试验（RCT）。采用 Cochrane 风险评估工具进行质量评价，Rev Man5.3 软件进行荟萃分析。
最终共纳入 37 项研究，涉及 34 项 RCT 和 8 种自身免疫性疾病（高尿酸血症和痛风、炎症性肠病关节炎、幼年特发性关节炎[JIA]、骨关节炎[OA]、骨质疏松和骨量减少、银屑病、类风湿关节炎[RA]、脊柱关节炎）。RA 涉及 10 项 RCT（632 名参与者），结果显示益生菌干预可降低 CRP。银屑病涉及 4 项 RCT（214 名参与者），结果显示益生菌干预可降低 PASI 评分。脊柱关节炎涉及 2 项 RCT（197 名参与者），结果显示益生菌干预可改善患者症状。骨质疏松和骨量减少涉及 10 项 RCT（1156 名参与者），显示益生菌干预可改善患者的骨密度。高尿酸血症和痛风涉及 4 项 RCT（294 名参与者），显示益生菌干预可降低患者的血尿酸。OA 涉及 1 项 RCT（433 名参与者），显示益生菌干预可改善患者症状。JIA 涉及 2 项 RCT（72 名参与者），显示益生菌干预可改善患者症状。炎症性肠病关节炎涉及 1 项 RCT（120 名参与者），显示益生菌干预可改善患者症状。所有这些 RCT 均表明益生菌不会增加不良反应的发生率。
益生菌补充剂可能改善高尿酸血症和痛风、炎症性肠病关节炎、JIA、OA、骨质疏松和骨量减少、银屑病、RA、脊柱关节炎。然而，未来需要更多的随机对照试验来确定益生菌的疗效和最佳剂量设计。
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021286425，标识符 CRD42021286425。
